Fund BasicsSee More
- Fund Family Amplify ETFs
- Assets Under Management 135,872,000
- Shares Outstanding, K 4,400
- 60-Month Beta 1.71
- Price/Earnings ttm 0.00
- Annual Dividend & Yield 0.10
- Most Recent Dividend 0.101
- Management Fee 0.75%
|Period||Period Low||Period High||Performance|
| || |
+1.05 (+3.67%)since 02/03/21
| || |
+11.52 (+63.38%)since 12/03/20
| || |
+19.28 (+185.06%)since 03/03/20
Though the start of February was upbeat, rising rate worries triggered a crash at month-end.
The flight to cyclical sectors benefited the major bourses last month despite the sell-off in high-growth and high-beta stocks.
CNBC's cannabis expert Tim Seymour discusses the outlook for the industry.
Last week was marked by the bitcoin rally, some Reddit bets and uptrend in some cyclical sectors.
After promoting GameStop (GME) and Silver, Reddit's discussion has now popularized marijuana stocks like Sundial Growers (up 78.8% on Feb 10) and Tilray (up more than 50% on Feb 10).
We have presented five ETFs that are easily crushing the Russell 2000 Index this year and are likely to continue their strong performance at least in the near term.
Jazz Pharmaceuticals (JAZZ) agreed to buy cannabinoid drug company GW Pharmaceuticals (GWPH) for $7.2 billion in cash and stock that has strengthened the bullish case for the cannabis industry.
The cannabis ETF has hit a new 52-week high. Are more gains in store?
A few top ETF stories ruled the month of January and deserve a close look in February.
This cannabis ETF hits a new 52-week high. Are more gains in store for this ETF?
|3rd Resistance Point||33.78|
|2nd Resistance Point||33.20|
|1st Resistance Point||32.10|
|1st Support Level||30.43|
|2nd Support Level||29.85|
|3rd Support Level||28.76|